key: cord-0994411-5ko5qv5q
authors: Traidl, Stephan; Angela, Yenny; Kapp, Alexander; Schefzyk, Matthias
title: Hemorrhagic rash on the legs
date: 2021-04-24
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.04.015
sha: 8ec427658a943d3e80ccfac2efaa3277e43cfe65
doc_id: 994411
cord_uid: 5ko5qv5q

nan

A 42-year-old woman presented with hemorrhagic macules and papules, especially affecting the lower extremity (Fig 1) . Two weeks prior to presentation, she had cough, diarrhea, malaise, and limb pain. Infection with COVID-19 was confirmed through polymerase chain reaction. The rash began as a pruritic eruption on her right tibia, progressing to the current presentation over 2 days. C-reactive protein level was found to be increased (60.4 mg/L; normal level, #5.0 mg/L). The measurement of kidney function and blood count revealed no anomalies. Two skin biopsies were taken: one for histologic examination and the other for direct immunofluorescence (Fig 2) . A. Schamberg diseaseeIncorrect. Although the distribution of Schamberg disease is often symmetrical on the lower extremities as in the present case, this condition does not account for the severe fibrinoid necrosis of the vessel walls as identified in the histology.

B. COVID-associated vasculopathyeIncorrect. Vasculopathy is defined by thickening of the intima due to the deposition of immunoglobulins, complement components, and fibrinogen without inflammatory lymphocyte infiltration. In the present case, fibrinoid necrosis and leukocytoclasia were present.

C. Skin-limited IgA vasculitiseCorrect. The patient showed a typical manifestation of leukocytoclastic vasculitis, which often occurs parainfectious. The fibrinoid necrosis of the vessel walls, nuclear dust from neutrophil fragmentation, and extravasation of red blood cells in addition to direct immunofluorescence staining with IgA are common characteristics of IgA vasculitis.

D. Thrombocytopenic purpuraeIncorrect. Laboratory findings showed no sign of thrombocytopenia.

Although hemorrhagic rash is one of the common symptoms of Rocky Mountain spotted fever, our patient had no history of potential tick exposure and was not in an endemic area. 

A. IbuprofeneIncorrect. Although ibuprofen has anti-inflammatory effects, it is not sufficient to treat vasculitis. Additionally, the potential adverse renal effects should be considered.

B. HeparineIncorrect. A study with 228 children investigated heparin in IgA vasculitis and suggested a reduced risk of persistent kidney disease. 3 However, the therapy is not justified due to the risk of severe side effects.

AdalimumabeIncorrect. Several studies have investigated the effect of adalimumab in a variety of vasculitis forms with mixed results. Regarding IgA vasculitis, there are case reports that presented an IgA vasculitis that was triggered by adalimumab. 4 Considering these reports, adalimumab is not recommended in IgA vasculitis.

D. DapsoneeCorrect. A recently published review on IgA vasculitis observed that dapsone was effective in refractory IgA vasculitis. 5 In our case, dapsone induced a stable remission of IgA vasculitis after a relapse under the glucocorticosteroid therapy.

CyclophosphamideeIncorrect. There is evidence that other immunosuppressants are more effective than cyclophosphamide. Although cyclophosphamide is a potential therapeutic option, side effects must be considered. Other treatments should be preferred, especially in the case of skin-limited IgA vasculitis.

None disclosed.

Multisystemic manifestations of IgA vasculitis

Determination of risk factors in children diagnosed with Henoch-Sch€ onlein purpura

Interventions for preventing and treating kidney disease in Henoch-Sch€ onlein purpura (HSP)

Adalimumab (TNF a inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient

Treatment of refractory IgA vasculitis with dapsone: a systematic review